Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

HROW

Harrow Inc

May 16 • 04:00PM ET

16.16

Dollar change +0.23
Percentage change 1.48	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWO VTWO VHT IWC ITOT VTWG FHLC

Index	RUT	P/E	-	EPS (ttm)	-0.91	Insider Own	14.99%	Shs Outstand	35.17M	Perf Week	57.05%
Market Cap	571.74M	Forward P/E	26.78	EPS next Y	0.60	Insider Trans	3.49%	Shs Float	30.08M	Perf Month	36.72%
Income	-31.33M	PEG	-	EPS next Q	-0.20	Inst Own	58.64%	Short Float	18.29%	Perf Quarter	45.59%
Sales	138.68M	P/S	4.12	EPS this Y	28.33%	Inst Trans	-4.54%	Short Ratio	10.59	Perf Half Y	96.83%
Book/sh	1.70	P/B	9.51	EPS next Y	212.25%	ROA	-12.23%	Short Interest	5.50M	Perf Year	-23.19%
Cash/sh	2.15	P/C	7.53	EPS next 5Y	15.00%	ROE	-76.44%	52W Range	7.60 - 24.19	Perf YTD	44.29%
Dividend Est.	-	P/FCF	89.76	EPS past 5Y	-	ROI	-12.49%	52W High	-33.20%	Beta	0.85
Dividend TTM	-	Quick Ratio	2.73	Sales past 5Y	27.34%	Gross Margin	69.77%	52W Low	112.63%	ATR (14)	1.00
Dividend Ex-Date	-	Current Ratio	2.99	EPS Y/Y TTM	-40.50%	Oper. Margin	-5.28%	RSI (14)	75.94	Volatility	11.15% 6.84%
Employees	315	Debt/Eq	3.19	Sales Y/Y TTM	49.79%	Profit Margin	-22.59%	Recom	1.00	Target Price	26.90
Option/Short	Yes / Yes	LT Debt/Eq	3.18	EPS Q/Q	-74.37%	Payout	-	Rel Volume	0.98	Prev Close	15.93
Sales Surprise	-4.77%	EPS Surprise	-74.71%	Sales Q/Q	32.50%	Earnings	May 13 AMC	Avg Volume	519.49K	Price	16.16
SMA20	44.83%	SMA50	39.33%	SMA200	29.70%	Trades		Volume	512,999	Change	1.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

May-15-24 07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-13-24 08:55PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:25PM	Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours (MT Newswires)
04:01PM	Harrow Announces First Quarter 2024 Financial Results (Business Wire)
07:00AM	Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial (Business Wire)
07:00AM	Loading…
Apr-25-24 07:00AM	Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 (Business Wire)
Apr-02-24 08:16AM	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing (Business Wire)
Mar-21-24 09:55AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 09:52PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
06:51PM	Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 (GuruFocus.com)
05:45PM	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-13-24 06:35AM	Harrow (HROW) Fell on Lowering the Guidance (Insider Monkey)
Mar-05-24 07:00AM	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-21-24 06:47AM	Heres How Harrow (HROW) Weighed on SRK Capitals Performance (Insider Monkey)
04:01PM	Loading…
Feb-15-24 04:01PM	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products (Business Wire)
Jan-29-24 07:00AM	Harrow Announces New Appointments to its Board of Directors (Business Wire)
Jan-11-24 07:00AM	Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease (Business Wire)
Jan-03-24 07:15AM	Melt Pharmaceuticals Provides Corporate Update (Business Wire)
07:00AM	Harrow Partners with Leading Healthcare Market Access Technology Platforms (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
01:03PM	Loading…
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 06:15PM	Harrow Health (HROW) Flat As Market Sinks: What You Should Know (Zacks)
Jun-16-23 06:00PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
May-17-23 08:00AM	Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 (Business Wire)
May-16-23 11:57AM	Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 11:21AM	Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks) -5.22%
May-12-23 01:48PM	Why Shares of Harrow Health Are Slumping Friday (Motley Fool) -18.58%
06:26AM	Q1 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:15PM	Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Harrow: Q1 Earnings Snapshot (AP Finance)
04:01PM	Harrow Announces First Quarter 2023 Financial Results (Business Wire)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 08:00AM	Harrow to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
May-02-23 04:42PM	Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May (Zacks)
09:40AM	Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. (Business Wire)
May-01-23 08:50AM	Here's Why Momentum in Harrow (HROW) Should Keep going (Zacks)
Apr-28-23 06:00PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
08:00AM	Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-24-23 08:43AM	Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:09AM	Bull Of The Day: Harrow Health (HROW) (Zacks)
Apr-20-23 08:31AM	5 Small Hidden Gems to Pick From a Rangebound Wall Street (Zacks)
Apr-19-23 06:15PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
08:31AM	Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings (Zacks)
Apr-18-23 06:24AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Apr-14-23 08:50AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Apr-13-23 06:15PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-23 09:40AM	Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year? (Zacks)
Apr-09-23 04:04PM	A New Roster of Top Stock-Fund Managers (The Wall Street Journal)
Apr-05-23 09:34AM	4 Medical Stocks to Buy as Rate Hike Cycle Nears End (Zacks)
Apr-04-23 05:37AM	Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus (Zacks)
Apr-03-23 06:53AM	5 Stocks With Recent Price Strength Amid March Rally (Zacks)
Mar-29-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-28-23 02:59PM	B. Riley Leads Financing to Support Harrow Health Acquisition (PR Newswire)
07:00AM	Harrow Announces New $100 Million Secured Credit Facility with Oaktree (Business Wire)
Mar-27-23 08:51AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Call Transcript (Insider Monkey) +16.50%
Mar-24-23 05:42AM	Q4 2022 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM	Harrow Announces Fourth Quarter and Year-End 2022 Financial Results (Business Wire)
Mar-13-23 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% (Business Wire)
Mar-06-23 08:00AM	Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance (Business Wire)
Mar-02-23 08:00AM	Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 (Business Wire)
Feb-16-23 06:42AM	Is Harrow Health (HROW) an Undervalued Stock? (Insider Monkey) +5.41%
Feb-15-23 07:00AM	Harrow Launches Next-Generation Compounded Atropine Formulations (Business Wire)
Feb-03-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +8.29%
Feb-02-23 06:30AM	Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 (Business Wire) +6.53%
Jan-23-23 07:00AM	Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products (Business Wire)
Jan-21-23 07:33AM	Investing in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gain (Simply Wall St.)
Jan-18-23 08:50AM	Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why (Zacks)
Jan-05-23 07:00AM	Harrow Announces Availability of Fortisite Formulations for In-Office Use (Business Wire)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Apr 25 '24	Buy	9.97	20,000	199,400	3,815,000	Apr 25 05:19 PM
Opaleye Management Inc.	10% Owner	Apr 24 '24	Buy	10.15	8,285	84,093	3,795,000	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 23 '24	Buy	10.29	11,715	120,547	3,786,715	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 19 '24	Buy	10.56	29,400	310,390	3,775,000	Apr 19 06:24 PM
Opaleye Management Inc.	10% Owner	Mar 28 '24	Buy	12.82	50,000	641,000	3,745,600	Mar 28 06:07 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Mar 22 '24	Buy	11.59	9,000	104,310	2,137,525	Mar 25 07:00 AM
Opaleye Management Inc.	10% Owner	Mar 20 '24	Buy	9.65	50,600	488,290	3,695,600	Mar 22 11:52 AM
SAHAREK JOHN P.	CEO of ImprimisRx	Mar 01 '24	Option Exercise	8.75	5,000	43,750	254,803	Mar 06 06:06 AM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 20 '24	Option Exercise	10.67	150,000	1,600,500	2,188,361	Feb 21 07:29 PM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 20 '24	Option Exercise	10.67	45,000	480,150	586,569	Feb 21 07:29 PM
SAHAREK JOHN P.	CEO of ImprimisRx	Feb 20 '24	Option Exercise	10.67	30,000	320,100	262,419	Feb 21 07:30 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 07 '24	Option Exercise	7.71	15,400	118,734	2,038,361	Feb 08 07:30 AM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 07 '24	Option Exercise	7.71	7,400	57,054	541,569	Feb 08 07:30 AM
BAUM MARK L	Chief Executive Officer	Nov 16 '23	Buy	8.11	7,500	60,825	2,022,961	Nov 16 04:45 PM
Opaleye Management Inc.	10% Owner	Nov 15 '23	Buy	8.03	25,000	200,735	3,645,000	Nov 16 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 20 '23	Buy	14.49	5,983	86,710	3,620,000	Sep 20 06:39 PM
Opaleye Management Inc.	10% Owner	Sep 19 '23	Buy	14.65	14,017	205,366	3,614,017	Sep 20 06:39 PM
Makary Martin A.	Director	Aug 14 '23	Buy	16.92	20,000	338,400	45,000	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Aug 14 '23	Buy	17.05	5,800	98,890	2,015,461	Aug 15 07:30 AM

Open in Screener

TCON

TRACON Pharmaceuticals Inc

May 16 • 04:00PM ET

1.53

Dollar change -0.09
Percentage change -5.56	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	2.36	EPS (ttm)	0.65	Insider Own	7.89%	Shs Outstand	2.68M	Perf Week	-16.39%
Market Cap	4.10M	Forward P/E	-	EPS next Y	-2.86	Insider Trans	0.00%	Shs Float	2.47M	Perf Month	-33.19%
Income	1.75M	PEG	-	EPS next Q	-1.41	Inst Own	10.60%	Short Float	6.20%	Perf Quarter	-59.78%
Sales	12.14M	P/S	0.34	EPS this Y	-89.70%	Inst Trans	-0.85%	Short Ratio	0.56	Perf Half Y	-57.26%
Book/sh	-0.66	P/B	-	EPS next Y	31.39%	ROA	19.78%	Short Interest	0.15M	Perf Year	-87.87%
Cash/sh	2.94	P/C	0.52	EPS next 5Y	-	ROE	-	52W Range	1.51 - 14.75	Perf YTD	-56.31%
Dividend Est.	-	P/FCF	0.67	EPS past 5Y	61.51%	ROI	-	52W High	-89.62%	Beta	1.27
Dividend TTM	-	Quick Ratio	0.80	Sales past 5Y	-40.00%	Gross Margin	99.88%	52W Low	0.99%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	0.80	EPS Y/Y TTM	102.58%	Oper. Margin	-23.03%	RSI (14)	33.83	Volatility	10.03% 9.93%
Employees	17	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	14.39%	Recom	1.67	Target Price	37.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	81.52%	Payout	-	Rel Volume	0.39	Prev Close	1.62
Sales Surprise	-	EPS Surprise	-11.76%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	272.08K	Price	1.53
SMA20	-17.24%	SMA50	-65.25%	SMA200	-62.85%	Trades		Volume	108,043	Change	-5.56%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Upgrade	BTIG Research	Neutral → Buy	$14
Feb-10-21	Initiated	Maxim Group	Buy	$24
Dec-23-19	Reiterated	H.C. Wainwright	Buy	$15 → $18
Mar-01-19	Reiterated	Needham	Buy	$7
Jun-13-17	Reiterated	Stifel	Buy	$14 → $6
Dec-21-16	Initiated	Jefferies	Buy	$10
Feb-01-16	Resumed	Oppenheimer	Outperform
Jul-29-15	Initiated	ROTH Capital	Buy	$18
Mar-02-15	Reiterated	Stifel	Buy	$16 → $20
Mar-02-15	Reiterated	Oppenheimer	Outperform	$22 → $26
Feb-24-15	Initiated	Stifel	Buy	$16
Feb-24-15	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

May-15-24 06:53AM	Q1 2024 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -17.77%
03:10AM	TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-14-24 08:56PM	TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Tracon: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Loading…
May-07-24 04:01PM	TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 (GlobeNewswire)
Apr-10-24 06:30AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 (InvestorPlace) -10.47%
Apr-08-24 09:10AM	TRACON Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -24.79%
Apr-03-24 08:00AM	TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned (GlobeNewswire) -47.18%
Mar-07-24 10:03AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript (Insider Monkey) +18.02%
Mar-05-24 04:29PM	Tracon: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 04:02PM	TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 (GlobeNewswire)
Dec-20-23 08:00AM	TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial (GlobeNewswire)
Nov-21-23 07:55AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? (InvestorPlace) +25.07%
07:32AM	Loading…
07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-20-23 08:00AM	TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment (GlobeNewswire)
Nov-13-23 09:29AM	Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today? (InvestorPlace) -7.08%
Nov-12-23 08:47AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:45AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today? (InvestorPlace) +43.94%
Nov-09-23 04:58PM	Tracon: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 04:02PM	TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 (GlobeNewswire) +11.35%
Sep-18-23 08:00AM	TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned (GlobeNewswire)
Sep-05-23 04:02PM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Aug-15-23 08:43AM	Q2 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM	Tracon: Q2 Earnings Snapshot (Associated Press Finance) -9.66%
04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:05PM	TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 (GlobeNewswire) +14.06%
08:00AM	Loading…
Jul-11-23 08:00AM	TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma (GlobeNewswire) +5.52%
Jun-20-23 08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Jun-16-23 08:00AM	TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference (GlobeNewswire)
Jun-15-23 08:00AM	TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma (GlobeNewswire) -5.91%
Jun-02-23 08:00AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +7.93%
May-30-23 08:00AM	TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 11:24AM	Q1 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM	Tracon: Q1 Earnings Snapshot (AP Finance)
04:02PM	TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 04:02PM	TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 (GlobeNewswire) +5.19%
Apr-25-23 07:41AM	TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab (GlobeNewswire) -46.63%
Apr-06-23 08:30AM	Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update (GlobeNewswire) +6.19%
Mar-14-23 12:00PM	Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.16%
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey) +8.33%
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -8.00%
Feb-28-23 04:02PM	TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 (GlobeNewswire)
Jan-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 01/20/2023 (Argus Research)
Jan-10-23 08:30AM	Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update (GlobeNewswire)
Dec-27-22 08:00AM	TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 (GlobeNewswire) +10.34%
Dec-14-22 11:29AM	TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Nov-21-22 08:00AM	TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma (GlobeNewswire)
Nov-14-22 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +9.03%
Oct-31-22 08:00AM	TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 (GlobeNewswire)
Oct-06-22 08:30AM	Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update (GlobeNewswire) +6.63%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned (GlobeNewswire)
Sep-14-22 08:00AM	TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS (GlobeNewswire)
Sep-07-22 08:00AM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-06-22 08:00AM	TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital (GlobeNewswire) -5.53%
Aug-29-22 08:00PM	US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (Business Wire)
11:45AM	TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Aug-10-22 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.11%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-08-22 08:00AM	TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Jul-27-22 08:05AM	TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022 (GlobeNewswire) +6.32%
Jul-26-22 08:05AM	TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter (GlobeNewswire)
Jun-02-22 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-16-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.57%
May-11-22 04:02PM	TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 08:05AM	TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022 (GlobeNewswire)
Apr-19-22 08:05AM	TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K. (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-23-22 08:05AM	TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire) +9.16%
Mar-15-22 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-22 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -6.85%
Mar-10-22 08:05AM	TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol (GlobeNewswire) +18.22%
Mar-04-22 08:05AM	TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022 (GlobeNewswire)
Feb-02-22 08:05AM	TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute (GlobeNewswire)
Jan-05-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire) -9.25%
Dec-27-21 08:00AM	TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial (GlobeNewswire) -20.16%
Nov-29-21 08:05AM	TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China (GlobeNewswire)
Nov-11-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-21 08:05AM	TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021 (GlobeNewswire)
Oct-13-21 08:00AM	TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors (GlobeNewswire)
Oct-11-21 01:27PM	TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications (Benzinga) +7.96%
08:00AM	TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001 (GlobeNewswire)
Sep-13-21 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Sep-07-21 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
07:29AM	TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments (Benzinga)
Sep-02-21 08:05AM	TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference (GlobeNewswire) +6.04%
Aug-11-21 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:05AM	TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-03-21 08:05AM	TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) -10.05%
Jul-28-21 08:05AM	TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021 (GlobeNewswire)
Jul-21-21 10:30PM	TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million (GlobeNewswire)
05:27PM	TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Jul-20-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award (GlobeNewswire) +5.10%

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Open in Screener

TARA

Protara Therapeutics Inc

May 16 • 04:00PM ET

3.74

Dollar change +0.03
Percentage change 0.81	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-3.74	Insider Own	19.88%	Shs Outstand	20.59M	Perf Week	25.50%
Market Cap	77.01M	Forward P/E	-	EPS next Y	-3.65	Insider Trans	-4.26%	Shs Float	16.50M	Perf Month	37.00%
Income	-42.47M	PEG	-	EPS next Q	-0.74	Inst Own	39.29%	Short Float	6.25%	Perf Quarter	5.95%
Sales	0.00M	P/S	-	EPS this Y	-0.45%	Inst Trans	-2.32%	Short Ratio	2.85	Perf Half Y	211.67%
Book/sh	5.11	P/B	0.73	EPS next Y	-1.84%	ROA	-48.67%	Short Interest	1.03M	Perf Year	7.16%
Cash/sh	2.68	P/C	1.39	EPS next 5Y	-	ROE	-55.45%	52W Range	1.04 - 5.24	Perf YTD	99.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.98%	ROI	-67.81%	52W High	-28.63%	Beta	1.91
Dividend TTM	-	Quick Ratio	10.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	259.62%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	10.53	EPS Y/Y TTM	34.41%	Oper. Margin	0.00%	RSI (14)	67.39	Volatility	12.90% 10.38%
Employees	27	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	27.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-21.41%	Payout	-	Rel Volume	1.53	Prev Close	3.71
Sales Surprise	-	EPS Surprise	-5.43%	Sales Q/Q	-	Earnings	May 02 BMO	Avg Volume	361.65K	Price	3.74
SMA20	24.84%	SMA50	10.01%	SMA200	54.00%	Trades		Volume	547,290	Change	0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Loading…
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Loading…
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
05:11PM	Loading…
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)
Dec-03-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-20 07:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-12-20 07:15AM	Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Nov-11-20 07:00AM	Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-04-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-20 03:12PM	What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry? (Simply Wall St.)
Sep-22-20 08:13AM	Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire)
Sep-21-20 04:01PM	Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.97%
Sep-08-20 07:00AM	Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications (GlobeNewswire) -6.09%
Sep-02-20 05:49PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-20 07:00AM	Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Jul-28-20 07:00AM	Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) +5.29%
Jul-24-20 07:00AM	Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors (GlobeNewswire)
Jul-03-20 06:34PM	Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) (Insider Monkey)
Jul-02-20 07:59PM	CORRECTION Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-20 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.74%
May-26-20 08:30AM	Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease (GlobeNewswire) +13.98%
May-13-20 08:00AM	Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview (GlobeNewswire) -8.46%
May-11-20 08:38AM	ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics (GlobeNewswire)
May-05-20 04:05PM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-20 07:00AM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-20 08:00AM	ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	May 10 '24	Sale	3.11	151,700	472,424	2,380,294	May 10 06:57 PM
Opaleye Management Inc.	10% Owner	May 09 '24	Sale	3.09	30,600	94,526	2,531,994	May 10 06:57 PM

Open in Screener

TELA

TELA Bio Inc

May 16 • 04:00PM ET

6.36

Dollar change +0.38
Percentage change 6.35	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC JFWD VTWG RYLD GSSC

Index	RUT	P/E	-	EPS (ttm)	-1.67	Insider Own	1.84%	Shs Outstand	24.49M	Perf Week	28.74%
Market Cap	156.84M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	262.76%	Shs Float	24.20M	Perf Month	23.02%
Income	-40.30M	PEG	-	EPS next Q	-0.46	Inst Own	58.98%	Short Float	4.65%	Perf Quarter	-13.59%
Sales	63.15M	P/S	2.48	EPS this Y	25.15%	Inst Trans	17.15%	Short Ratio	6.93	Perf Half Y	40.09%
Book/sh	0.58	P/B	10.90	EPS next Y	24.14%	ROA	-61.70%	Short Interest	1.13M	Perf Year	-32.84%
Cash/sh	1.51	P/C	4.22	EPS next 5Y	-	ROE	-459.89%	52W Range	4.23 - 11.26	Perf YTD	-3.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.17%	ROI	-73.20%	52W High	-43.52%	Beta	1.09
Dividend TTM	-	Quick Ratio	3.23	Sales past 5Y	49.61%	Gross Margin	68.97%	52W Low	50.18%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	4.13	EPS Y/Y TTM	37.33%	Oper. Margin	-71.62%	RSI (14)	75.06	Volatility	7.29% 5.64%
Employees	227	Debt/Eq	2.87	Sales Y/Y TTM	40.03%	Profit Margin	-63.82%	Recom	1.00	Target Price	14.20
Option/Short	Yes / Yes	LT Debt/Eq	2.83	EPS Q/Q	63.26%	Payout	-	Rel Volume	0.58	Prev Close	5.98
Sales Surprise	1.74%	EPS Surprise	52.95%	Sales Q/Q	39.42%	Earnings	May 09 AMC	Avg Volume	162.48K	Price	6.36
SMA20	29.99%	SMA50	22.78%	SMA200	-3.33%	Trades		Volume	94,537	Change	6.35%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-22	Initiated	Lake Street	Buy	$17
Dec-03-19	Initiated	Piper Jaffray	Overweight
Dec-03-19	Initiated	JMP Securities	Mkt Outperform
Dec-03-19	Initiated	Jefferies	Buy
Dec-03-19	Initiated	Canaccord Genuity	Buy

May-13-24 11:01AM	TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.80%
03:51PM	TELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued Growth (GuruFocus.com)
10:15AM	Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating (MT Newswires)
May-09-24 04:05PM	TELA Bio Reports First Quarter 2024 Financial Results (GlobeNewswire)
04:10PM	Loading…
May-02-24 04:10PM	MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-25-24 07:00AM	TELA Bio to Announce First Quarter 2024 Financial Results (GlobeNewswire)
Apr-15-24 07:00AM	TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR - Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures (GlobeNewswire)
Apr-08-24 07:00AM	TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy (GlobeNewswire)
Mar-22-24 09:46AM	TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.10%
07:07AM	Q4 2023 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 08:53PM	TELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:32PM	TELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
05:30PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results (GlobeNewswire)
07:00AM	Loading…
07:00AM	TELA Bio Announces U.S. Commercial Launch of LIQUIFIX the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery (GlobeNewswire)
Mar-20-24 07:00AM	TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX (GlobeNewswire)
07:00AM	MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing (GlobeNewswire)
Feb-29-24 07:00AM	TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-23-24 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-19-24 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-23 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-23 07:00AM	TELA Bio to Take Part in Connecting the Dots (GlobeNewswire) -6.68%
Nov-16-23 07:00AM	TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference (GlobeNewswire)
Nov-12-23 12:20PM	TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.37%
Nov-09-23 04:05PM	TELA Bio Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 07:00AM	TELA Bio to Announce Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-18-23 04:05PM	TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-16-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery (GlobeNewswire)
10:03AM	Loading…
Aug-11-23 10:03AM	TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:18AM	Q2 2023 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 06:05PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:03PM	TELA Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-26-23 07:00AM	TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-06-23 10:09AM	Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains? (Zacks)
Jun-18-23 07:51PM	Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength? (Zacks)
Jun-15-23 07:00AM	New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options (GlobeNewswire) -7.05%
May-25-23 07:00AM	TELA Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-23 10:30AM	What You Can Learn From TELA Bio, Inc.'s (NASDAQ:TELA) P/S (Simply Wall St.)
May-19-23 07:00AM	TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab (GlobeNewswire)
May-12-23 07:44AM	Q1 2023 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:25PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:02PM	TELA Bio Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:00AM	TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference (GlobeNewswire)
May-08-23 04:30PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 07:00AM	TELA Bio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-30-23 08:26AM	TELA Bio, Inc. (NASDAQ:TELA) stock most popular amongst private equity firms who own 36%, while individual investors hold 26% (Simply Wall St.)
Apr-28-23 06:47PM	Dlocal, Augmedix See Activist Investor Action (Barrons.com)
06:47PM	Dlocal and Augmedix Stock See Action From Activist Investors (Barrons.com)
Apr-27-23 07:00AM	TELA Bio to Announce First Quarter 2023 Financial Results (GlobeNewswire)
Apr-18-23 11:00PM	TELA Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	TELA Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-03-23 06:14AM	TELA Bio's (NASDAQ:TELA) investors will be pleased with their notable 34% return over the last three years (Simply Wall St.)
Mar-29-23 07:00AM	TELA Bios OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023 (GlobeNewswire)
Mar-24-23 07:15AM	TELA Bio, Inc. (NASDAQ:TELA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 07:00AM	TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery (GlobeNewswire)
Mar-22-23 06:01AM	Q4 2022 TELA Bio Inc Earnings Call (Thomson Reuters StreetEvents) -5.91%
Mar-21-23 05:15PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications (GlobeNewswire) +5.74%
Feb-28-23 07:00AM	TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-24-23 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.05%
Feb-21-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques (GlobeNewswire)
Feb-14-23 07:00AM	TELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization (GlobeNewswire)
Jan-20-23 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 07:00AM	TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds (GlobeNewswire)
Dec-23-22 05:46AM	One TELA Bio, Inc. (NASDAQ:TELA) insider upped their stake by 342% in the previous year (Simply Wall St.)
Dec-21-22 07:00AM	TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-22 04:02PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-22 07:00AM	TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-12-22 07:42AM	TELA Bio Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 05:25PM	TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -8.71%
04:01PM	TELA Bio Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 07:00AM	TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire) -7.19%
Oct-28-22 04:05PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-27-22 07:00AM	TELA Bio to Announce Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 07:00AM	TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair (GlobeNewswire)
Oct-24-22 10:24AM	The past year for TELA Bio (NASDAQ:TELA) investors has not been profitable (Simply Wall St.)
Sep-01-22 07:00AM	TELA Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-22 04:01PM	TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-19-22 10:52AM	Lab Notes: Larimar readying response to the FDA's clinical hold; Tela Bio completes $36.8M stock sale (American City Business Journals)
Aug-18-22 04:01PM	TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Aug-16-22 12:01PM	Tela Bio prices $32M public stock offering; share price drops (American City Business Journals) -11.15%
Aug-15-22 10:20PM	TELA Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	TELA Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-10-22 10:30PM	TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript (Motley Fool)
05:35PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	TELA Bio Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-05-22 07:00AM	TELA Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-04-22 07:00AM	TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting (GlobeNewswire)
Jul-29-22 04:01PM	TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-27-22 07:00AM	TELA Bio to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-20-22 07:00AM	TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc. (GlobeNewswire)
Jul-08-22 06:45AM	Is TELA Bio, Inc. (NASDAQ:TELA) Popular Amongst Institutions? (Simply Wall St.)
Jun-24-22 08:52AM	uniQure (QURE) Moves 27% Higher: Will This Strength Last? (Zacks)
Jun-23-22 11:02AM	TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar? (Zacks) +7.08%
Jun-10-22 06:15AM	Trade Alert: The CFO & COO Of TELA Bio, Inc. (NASDAQ:TELA), Roberto Cuca, Has Just Spent US$83k Buying 342% More Shares (Simply Wall St.) -8.15%
Jun-02-22 07:00AM	TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference (GlobeNewswire)

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Firestone Gregory A.	Chief Business Officer	Dec 05 '23	Buy	5.65	2,600	14,688	35,511	Dec 07 04:02 PM
KOBLISH ANTONY	Chief Executive Officer	Nov 14 '23	Buy	4.54	11,000	49,976	303,634	Nov 14 08:01 PM
Cuca Roberto	COO and CFO	Nov 14 '23	Buy	4.49	10,000	44,938	62,371	Nov 14 08:02 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HROW

Harrow Inc

TCON

TRACON Pharmaceuticals Inc

TARA

Protara Therapeutics Inc

TELA

TELA Bio Inc

Upgrade your FINVIZ experience